TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook
TGTX•TG Therapeutics said third-quarter product revenue rose 51% year over year to $240.04 million, driven by BRIUMVI sales. It raised its 2026 global revenue outlook to about $1 billion and its U.S. BRIUMVI revenue forecast to $915 million–$920 million.
1. Revenue and outlook
Third-quarter product revenue increased 51% year over year to $240.04 million, with the company attributing the growth to U.S. BRIUMVI sales. TG Therapeutics raised its 2026 total global revenue guidance to about $1 billion from $950 million and lifted its U.S. BRIUMVI net product revenue forecast to $915 million–$920 million from $890 million–$905 million.
2. Expenses and buyback
The company reaffirmed 2026 operating expense guidance of $450 million–$500 million, including costs for subcutaneous BRIUMVI. It said higher selling, general and administrative expenses reflected increased marketing and media spending, while higher research and development expenses mainly reflected subcutaneous BRIUMVI manufacturing and clinical trial costs. TG Therapeutics repurchased $100 million of shares in the third quarter.
